arrow
C

Catherine J. Lee

Fred Hutch Cancer Center
H指数:21
被引数:1,780

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comparison of Late Effects and Quality of Life by Donor Type in Long-Term Survivors of Severe Aplastic Anemia after Hematopoietic Cell Transplantation

比较造血干细胞移植后重型再生障碍性贫血长期存活者中供者类型对晚期效应和生活质量的影响

2026-08-210
PRE
Transportability to the European Population of Efficacy of Belumosudil as Compared With Physician's Choice of Best Available Therapy for the Treatment of Chronic Graft Versus Host Disease

与医生选择的最佳可用疗法相比,Belumosudil治疗慢性移植物抗宿主病在欧洲人群中有效性的可转移性

2026-06-010
OAAI
Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma

利萨库肽马瑞卢赛尔在复发或难治性大B细胞淋巴瘤患者中的真实世界结局

Blood
IF23.1
2026-03-050
OA
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia

社会决定因素对成人复发/难治性B细胞急性淋巴细胞白血病患者brexucabtagene autoleucel治疗结局的影响

2025-08-230
OAAI
Assessing Social Determinants of Health in Transplantation and CAR-T Recipients: Expert Panel Recommendations from the Survivorship Special Interest Group of ASTCT

评估移植和CAR-T接受者的健康社会决定因素:ASTCT幸存者特别兴趣小组专家委员会的建议

2025-07-230
PRE
Assessing Quality of Life and Symptoms in Transplantation and CAR-T Recipients: Expert Panel Recommendations from the Survivorship Special Interest Group of ASTCT

评估移植和CAR-T接受者的生活质量与症状:ASTCT生存期特别兴趣小组专家委员会建议

2025-07-010
PRE
Assessing Cognitive Function in Transplantation and CAR-T Recipients: Expert Recommendations from the Survivorship, Aging and Biobehavioral Special Interest Groups of ASTCT

评估移植和CAR-T接受者的认知功能:ASTCT生存率、老龄化和生物行为特别兴趣小组的专家建议

2025-07-010
PRE
Assessing Physical Function in Transplantation and CAR-T Recipients: Expert Recommendations from the Survivorship, Aging and Biobehavioral Special Interest Groups of ASTCT

评估移植和CAR-T接受者的躯体功能:ASTCT生存、衰老与生物行为特别兴趣小组的专家建议

2025-06-010
PRE
Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement

Brexucabtagene autoleucel在伴有CNS受累的复发/难治性急性淋巴细胞白血病患者中的疗效

2025-05-090
OAAI
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL
2024-12-102
OAAI
Decreasing chronic graft-versus-host disease rates in all populations
2024-11-150
OAAI
Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above

Brexucabtagene autoleucel治疗60岁及以上患者复发/难治性B细胞急性淋巴细胞白血病的有效性与安全性

BLOOD
IF23.1
2024-11-051
PRE
Trials in Progress: Decoy-Resistant Interleukin-18 (DR-18) for Relapse or Pre-Emptive Treatment of Measurable Residual Disease after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome (DR. DREAM), a Phase I Trial

临床试验:针对异基因造血细胞移植后急性髓系白血病和骨髓增生异常综合征患者可测量残留病灶的复发或预防性治疗,使用抗诱饵型白介素-18(DR-18)(DR. DREAM),一项I期临床试验

BLOOD
IF23.1
2024-11-050
PRE